ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 003

Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers

Julia Harris1, Esi Morgan 2, Janalee Taylor 2, Tingting Qiu 3, Nancy Griffin 3, Anne Paul 4, C. April Bingham 5, Danielle Bullock 6, Kerry Ferraro 7, Mileka Gilbert 8, Y. Ingrid Goh 9, Olha Halyabar 10, Karla Jones 11, Melanie Kohlheim 12, Daniel J. Lovell 13, Emily Smitherman 14, Anjie Vago 7, Jennifer Weiss 15, Cagri Yildirim-Toruner 11, Angela Young 7, Michelle Batthish 16, Beth Gottlieb 17, Melissa Hazen 18, Ronald Laxer 19, Tzielan Lee 20, Melissa Mannion 14, Judyann Olson 21, Michael Shishov 22, Salma Siddique 23, Charles Spencer 24, Mary Toth 25, Sheetal Vora 26 and Jon Burnham 27, 1Children's Mercy Kansas City, Overland Park, 2Cincinnati Children's Hospital, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, 4Cincinnati Children's Hospital Medical Centre, Cincinnati, 5Penn State Children's Hospital, Allentown, 6University of Minnesota, Minneapolis, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Medical University of South Carolina, Charleston, South Carolina, 9The Hospital for Sick Children, Toronto, Canada, 10Children's Hospital/Boston Medical Center, Boston, 11Nationwide Children's Hospital, Columbus, 12, 13Cincinnati, 14University of Alabama at Birmingham, Birmingham, 15Hackensack University Medical Center, Hackensack, 16McMaster University, Hamilton, Canada, 17Cohen Children's Medical Center, Lake Success, 18Boston, 19The Hospital for Sick Children and University of Toronto, Toronto, Canada, 20Stanford Children's, Palo Alto, 21Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 22Phoenix Children's Hospital, Phoenix, 23Nemours/A.I.duPont Hospital for Children, Wilmington, 24Jackson, 25Nemours Foundation, Orlando, 26Atrium Health Levine Children's Hospital, Charlotte, 27Children's Hospital of Philadelphia, Philadelphia

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: juvenile idiopathic arthritis (JIA), Shared dicision making, treatment

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Plenary Abstracts Session 1

Session Type: Plenary Session I

Session Time: 2:30PM-3:30PM

Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment target of disease activity and emphasizes tight disease control while utilizing shared decision making (SDM). Based on the literature and success at a pilot site, centers in the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) began a collaborative improvement project in February 2019 using quality improvement (QI) methods to test, implement, and disseminate T2T interventions. PR-COIN focused on reliable deployment of three T2T processes: standardized disease activity assessment, setting a treatment target with patient/family, and use of clinical decision support (CDS). Our objective was to implement T2T with high reliability in 80% of PR-COIN centers with initial focus on standardized assessment and target setting.

Methods: PR-COIN co-produced educational materials with patients/families to train providers and staff on T2T implementation and to inform families of this treatment approach. The network designed a staged implementation plan, adapted an evidence and consensus-based treatment algorithm, and created a data submission platform to monitor performance over time via run charts. PR-COIN hosts interactive monthly webinars and provides QI coaching. T2T interventions were being implemented in 3 steps on extended oligoarticular and polyarticular JIA patients: 1) standardize assessment and review of the clinical Juvenile Arthritis Disease Activity Score (cJADAS10), which includes the physician global assessment, active joint count, and patient global assessment, 2) set treatment target with the patient/family utilizing SDM and compare it to current disease activity, and 3) use of CDS. Sites progress to the next step once reliable process implementation (≥80%) is demonstrated in a sample of eligible patients.

Results: As of November 2019, 16 centers are participating in T2T. All centers completed on-site training and use QI methodology, and 14 of 16 centers (87.5%) submitted performance data. Seven sites (43.8%) are currently at high reliability performance for Step 1 and eight sites (50%) for Step 2 (Figure 1). Centers achieving 80% reliability on Steps 1 and 2 are beginning implementation of Step 3. A sample of patient-level data indicates that providers completed Step 1 activities in 185 of 218 encounters (84.9%) in November 2019, which was higher than the data median (52.5%) since project implementation (Figure 2). For Step 2, providers set treatment targets in 178 of 185 encounters (96.2%; Figure 3) and compared the cJADAS10 to the treatment target in 89% of encounters. Use of CDS (Step 3) was performed by three sites on 27 of 218 sampled patients (12%).

Conclusion: PR-COIN co-produced educational materials and its centers are implementing T2T interventions in clinical practice using QI methodology. Performance measurement shows half of sites have effectively integrated Steps 1 and 2 into the process of care and will now focus on Step 3 (CDS), which may require additional support and design for reliable and sustainable implementation.

Figure 1. Percent of PR_COIN centers that are at highly reliable performance at each level of T2T implementation.

Figure 2. Step 1 _ Standardized assessment and review of components of the clinical Juvenile Arthritis Disease Activity Score (cJADAS10).

Figure 3. Step 2 _ Use shared decision making (SDM) concepts to select treatment target with the family.


Disclosure: J. Harris, None; E. Morgan, None; J. Taylor, None; T. Qiu, None; N. Griffin, None; A. Paul, None; C. Bingham, None; D. Bullock, None; K. Ferraro, None; M. Gilbert, None; Y. Goh, None; O. Halyabar, None; K. Jones, None; M. Kohlheim, None; D. Lovell, AstraZeneca Pharm, 1, Boehringer Ingelheim, 1, Bristol Myers Squibb, 1, Forest Research, 1, GSK, 1, Janssen, 1, Pfizer, 1, UBC, 1; E. Smitherman, None; A. Vago, None; J. Weiss, None; C. Yildirim-Toruner, None; A. Young, None; M. Batthish, Abbvie, 1; B. Gottlieb, None; M. Hazen, None; R. Laxer, None; T. Lee, None; M. Mannion, None; J. Olson, None; M. Shishov, None; S. Siddique, None; C. Spencer, None; M. Toth, None; S. Vora, None; J. Burnham, None.

To cite this abstract in AMA style:

Harris J, Morgan E, Taylor J, Qiu T, Griffin N, Paul A, Bingham C, Bullock D, Ferraro K, Gilbert M, Goh Y, Halyabar O, Jones K, Kohlheim M, Lovell D, Smitherman E, Vago A, Weiss J, Yildirim-Toruner C, Young A, Batthish M, Gottlieb B, Hazen M, Laxer R, Lee T, Mannion M, Olson J, Shishov M, Siddique S, Spencer C, Toth M, Vora S, Burnham J. Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/implementing-treat-to-target-approach-in-the-care-of-juvenile-idiopathic-arthritis-across-a-network-of-pediatric-rheumatology-centers/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementing-treat-to-target-approach-in-the-care-of-juvenile-idiopathic-arthritis-across-a-network-of-pediatric-rheumatology-centers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology